Testing Repeat Radiation Therapy for Recurrent Non-small Cell Lung Cancer
NCT07835789 is a phase 2 interventional trial sponsored by NRG Oncology. As of 21 Nov 2026, it is not yet recruiting. It studies Systemic Chemotherapy in Locally Recurrent Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8 and 1 more condition. The registry lists an enrollment of 138 participants. The registry lists a start date of 18 Dec 2026 and a primary completion date of 30 Sept 2029. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT07835789 |
| Status | Not yet recruiting |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | NRG Oncology |
| Enrollment | 138 |
| Conditions | Locally Recurrent Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8 and Stage III Lung Cancer AJCC v8 |
| Drugs | Systemic Chemotherapy |
| Start | 18 Dec 2026 |
| Primary completion | 30 Sept 2029 |
| Study completion | 30 Sept 2034 |
| Last update posted | 23 Sept 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
No facility list is in our current data snapshot for this study. The registry record on ClinicalTrials.gov ↗ carries any published locations. Why? →
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT07835789
Each answer restates registry values shown on this page.
What is NCT07835789?
NCT07835789 is a phase 2 interventional trial sponsored by NRG Oncology. It studies Systemic Chemotherapy in Locally Recurrent Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8 and 1 more condition.
Is NCT07835789 recruiting?
As of 21 Nov 2026, it is not yet recruiting.
Who leads NCT07835789?
The registry names Nitin Ohri (principal investigator, NRG Oncology) as the overall official.
Which drugs does NCT07835789 study?
The registered drug and biological interventions are Systemic Chemotherapy.
When is NCT07835789 expected to complete?
The registry lists a primary completion date of 30 Sept 2029 and a study completion date of 30 Sept 2034. The sponsor last updated the record on 23 Sept 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.